HistoSonics, Inc.

HistoSonics, Inc. is proud to announce the first patients were enrolled in our novel prospective master protocol study, called BOOMBOX, designed to evaluate the real-world use of histotripsy for treatment of liver tumors. BOOMBOX will provide important data for up to 5,000 patients treated across a growing global base of multi-disciplinary histotripsy providers, capturing treatment data across diverse tumor types and disease stages in patients with varying interventional needs, and amongst multiple clinical specialties.  Dr. Randy Zuckerman at Renown Health and Dr. Terence Jackson at Northeast Georgia Health System led all histotripsy programs as the first to enroll subjects into BOOMBOX'S novel master study program. HistoSonics, Inc. appreciates their partnership in advancing the science and clinical use of histotripsy alongside many other leading centers working to enroll patients in BOOMBOX. HistoSonics, Inc. is dedicated to developing the clinical evidence that supports the use of histotripsy where patients and their families may benefit the most. #InnovationPartners #Histotripsy #MinimallyInvasiveIsntMinimalEnough

HistoSonics, Inc. is extremely proud to celebrate Veterans Day alongside our partner Fidelis Sustainability Distribution LLC as we honor those men and women who serve and who have served the United States of America with honor, courage and commitment. Our recent $90M, multi-year contract with the Veterans Health Administration (VHA) to provide Veterans early access to innovative, non-invasive tumor treatments via the novel Edison Histotripsy System demonstrates our shared dedication to improving the lives of each and every Veteran who may benefit. Thank you to each and every military member and military family member for your service. #HistoSonics #FidelisSustainabilityDistributionLLC #VeteransDay

HistoSonics, Inc. is excited to announce today that we have been awarded an exclusive contract to provide Veteran’s Affairs hospitals across the United States access to their novel non-invasive Edison Histotripsy Systems. The contract, the work of the Veterans Health Administration (VHA) and the Strategic Acquisition Center (SAC), establishes a $90 million ongoing schedule to develop histotripsy programs at key VA Hospitals. The announced VA contract is the culmination of a multi-year effort by HistoSonics, the company called Project Hero, to ensure meaningful value for Veterans and their families, VHA clinicians, administrators, and caregivers. “Too frequently, Veterans do not have early access to meaningful innovation in health care, so it has been a mission for our team to partner with the VA in bringing histotripsy to our Veterans as soon as possible,” said Mike Blue HistoSonics CEO and President. “We believe that histotripsy is especially well-suited as a therapy for those who served with honor and are due the best healthcare we can provide,” added Blue. #InnovationForVeterans #HistoSonics #Histotripsy The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events.

HistoSonics, Inc. is excited to participate in #ASTRO2024 September 29th - October 1st in Washington, DC. with our now FDA cleared Edison Histotripsy System using non-invasive sonic beam therapy to destroy targeted tumors and tissues using only the mechanical forces of histotripsy. "Meet Edison" at Booth #2709 where we will have hands-on demonstrations of histotripsy so you can target, plan and deliver non-invasive tumor liquefying histotripsy, and learn more about histotripsy's current role in clinical practice for the treatment of liver tumors. We invite all at #ASTRO2024 to #MeetEdison! We look forward to #ASTRO2024 in Washington, DC. and towards sharing how histotripsy is making a meaningful improvement in the lives of patients around the world. #PartnersInInnovation #HistoSonics #Histotripsy

HistoSonics, Inc. Is proud to have results from the pivotal #HOPE4LIVER Trials presented at @CIO2024 by Mishal Mendiratta-Lala MD, University of Michigan. #HOPE4LIVER Trial results were recently published in the journal Radiology. https://lnkd.in/eue6rUn8 Histotripsy is a new category of care being championed by many of the worlds most innovative physicians to improve the lives of patients suffering with liver tumors. We are honored to partner with physicians and institutions who share our purpose in advancing patients health utilizing non-invasive histotripsy. #PartnersInInnovation #MinimallyInvasiveIsntMinimalEnough #Histotripsy

HistoSonics, Inc. is extremely proud to announce the publication of our pivotal #HOPE4LIVER Trials data today. The prospective, international, multi-center, single arm #HOPE4LIVER Trials were designed to evaluate the safety and efficacy of histotripsy for the non-invasive destruction of primary (hepatocellular carcinoma) and metastatic liver tumors. Safety and efficacy were measured against performance goals established using real-world evidence from ablative therapies. The trials met the co-primary endpoints for technical success and safety, and this outcome is key as the investigators treated both primary and metastatic disease and represented a diverse group of liver experts with no prior experience performing histotripsy, signaling a quick learning curve. As a result of these early data, HistoSonics initiated planned commercialization of the Edison System in the first half of 2024, rapidly establishing histotripsy programs in leading academic and private institutions across the US and globally. To date, the accelerated clinical adoption of histotripsy has led to hundreds of histotripsy procedures completed by liver surgeons, interventional radiologists, and radiation oncologists with a high rate of success. These data are being prepared for publication later this year. Furthermore, longer-term 12-month efficacy data from #HOPE4LIVER is in analysis and in preparation for publication. We recognize the courage of the many patients and families who participated in these groundbreaking trials. Also, we are thankful to partner with visionary clinicians and hospital leaders who continue to champion histotripsy as a new category of care for their diverse patient populations. #Histotripsy #MinimallyInvasiveIsntMinimalEnough #HistoSonics

HistoSonics, Inc. is honored to establish our first histotripsy partnership in Hong Kong with the University of Hong Kong receiving their HistoSonics Histotripsy System as part of a generous philanthropic donation from the Li Ka Shing Foundation #LKSF and its founder, Mr. Li Ka-shing. Chinese University of Hong Kong is set to receive a second donated HistoSonics Histotripsy System from the Foundation early next year to complete the initial gift from Mr. Li. The Foundation, known globally for philanthropic leadership in education, anti-poverty programs and medical innovation, and HistoSonics share a mission to meaningfully help society through innovative healthcare. We at HistoSonics, Inc. are confident that histotripsy can begin to make an immediate impact on the quality of life of patients who need it most in this region, many who suffer from diseases that cause liver tumors. “We could not be more excited to partner with these two prestigious university hospitals to be the first in Hong Kong to offer our novel therapy to their patients,” said Mike Blue, HistoSonics CEO and President. “We would like to thank Mr. Li for his extremely charitable donation and the Li Ka Shing Foundation team for a phenomenal launch of histotripsy in Hong Kong, and we look forward to continuing our already strong relationship”, added Blue. #HistoSonics #Histotripsy #LKSF #PartnersInInnovation https://lnkd.in/gWN2d7hQ

HistoSonics, Inc. appreciates the Nasdaq for promoting our $102M Series D financing news today. Thanks to Alpha Wave Global , a world leader in growth stage investments, who led the round with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. #HistoSonics #Histotripsy #Nasdaq

HistoSonics, Inc. appreciates the NYSE for promoting our $102M Series D financing news today. Thanks to Alpha Wave Global , a world leader in growth stage investments, who led the round with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. #HistoSonics #Histotripsy #NYSE

HistoSonics, Inc. is honored to announce the completion of an oversubscribed $102 million Series D financing which will be used to accelerate category defining advancements to our non-invasive histotripsy platforms, support commercial growth in the US and in planned global markets, and initiate the company’s innovative, prospective BOOMBOX Master Study. The round was led by Alpha Wave Global, a world leader in growth stage investments, with participation from new investors Amzak Capital Management and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. We are excited to have such experienced investors join our team at HistoSonics, and whose investment reinforces our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. #TeamHisto #Histotripsy #MinimallyInvasiveneIsntMinimalEnough https://lnkd.in/gZy6W9qK